Safety and effectiveness of tofacitinib in ulcerative colitis: Data from TOFA-UC, a SN-IBD study.

[1]  M. Dubinsky,et al.  Review article: guide to tofacitinib dosing in patients with ulcerative colitis , 2022, Alimentary pharmacology & therapeutics.

[2]  S. Bonovas,et al.  Use of biologics and small molecule drugs for the management of moderate to severe ulcerative colitis: IG-IBD clinical guidelines based on the GRADE methodology. , 2022, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[3]  S. Bonovas,et al.  Use of biologics and small molecule drugs for the management of moderate to severe ulcerative colitis: IG-IBD technical review based on the GRADE methodology. , 2022, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[4]  Deepak L. Bhatt,et al.  Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. , 2022, The New England journal of medicine.

[5]  J. Gisbert,et al.  ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment. , 2021, Journal of Crohn's & colitis.

[6]  K. Tripathi,et al.  Effectiveness and Safety of Tofacitinib for Ulcerative Colitis , 2021, Journal of clinical gastroenterology.

[7]  A. Orlando,et al.  Effectiveness and safety of tofacitinib for the treatment of ulcerative colitis: A single-arm meta-analysis of observational studies. , 2021, Digestive and Liver Disease.

[8]  C. Taxonera,et al.  Real-World Effectiveness and Safety of Tofacitinib in Patients With Ulcerative Colitis: Systematic Review With Meta-Analysis. , 2021, Inflammatory bowel diseases.

[9]  S. Bonovas,et al.  Systematic review with meta‐analysis: biologics and risk of infection or cancer in elderly patients with inflammatory bowel disease , 2020, Alimentary pharmacology & therapeutics.

[10]  F. Macaluso,et al.  JAK inhibition as a therapeutic strategy for inflammatory bowel disease. , 2020, Current drug metabolism.

[11]  Siddharth Singh,et al.  AGA Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Colitis. , 2020, Gastroenterology.

[12]  S. Bonovas,et al.  Efficacy and safety of biologic agents and tofacitinib in moderate-to-severe ulcerative colitis: A systematic overview of meta-analyses , 2019, United European gastroenterology journal.

[13]  S. Targan,et al.  Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis. , 2019, The New England journal of medicine.

[14]  B. Sands,et al.  Safety of Tofacitinib for Treatment of Ulcerative Colitis, Based on 4.4 Years of Data From Global Clinical Trials. , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[15]  J. Colombel.  Herpes Zoster in Patients Receiving JAK Inhibitors For Ulcerative Colitis: Mechanism, Epidemiology, Management, and Prevention , 2018, Inflammatory bowel diseases.

[16]  S. Vermeire,et al.  Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis , 2017, The New England journal of medicine.

[17]  M. Cottone,et al.  The biologics of ulcerative colitis , 2017, Expert opinion on biological therapy.

[18]  L. Peyrin-Biroulet,et al.  Next generation of small molecules in inflammatory bowel disease , 2016, Gut.

[19]  P. Gionchetti,et al.  Expert consensus paper on the use of Vedolizumab for the management of patients with moderate-to-severe Inflammatory Bowel Disease. , 2016, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[20]  Siddharth Singh,et al.  Risk of cerebrovascular accidents and ischemic heart disease in patients with inflammatory bowel disease: a systematic review and meta-analysis. , 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[21]  H. Sørensen,et al.  Risk of cancer in patients with inflammatory bowel diseases: a nationwide population-based cohort study with 30 years of follow-up evaluation. , 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[22]  L. Peyrin-Biroulet,et al.  Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies. , 2012, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[23]  M. Schemper,et al.  A solution to the problem of separation in logistic regression , 2002, Statistics in medicine.

[24]  F. Carbonnel,et al.  Impact of cessation of smoking on the course of ulcerative colitis , 2001, American Journal of Gastroenterology.

[25]  D. Firth.  Bias reduction of maximum likelihood estimates , 1993 .